Daniel Woolson
CIK 1698998 · View on SEC EDGAR ↗
First SEC filing: May 18, 2018 · Latest: May 18, 2018
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Aug. 13, 2026 | ICUI | S | 5,417 | $181.33 | $982,265 | 17,062 Direct | -24.10% | Disposed | 3.0% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Initial ownership (Form 3) 3 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
ICUI
Corporate Vice President, General Manager - Infusion Systems| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $395,192 | — | $1,350,135 | — | $360,000 | — | $11,500 | $2,116,827 |
| 2024 | $375,000 | — | $1,350,190 | — | $326,250 | — | $17,250 | $2,068,690 |
| 2023 | $375,000 | $17,550 | $1,666,475 | — | $135,000 | — | $16,500 | $2,210,525 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.